Cancer Biology & Therapy

Cancer Biology & Therapy is a fully open access journal published by Taylor & Francis, founded in 2002, that examines the molecular basis of cancer with translational relevance to diagnosis and therapy, with a 2025 Journal Impact Factor of 5.7.《癌症生物学与治疗》（Cancer Biology & Therapy）由（Taylor & Francis）出版，2002 年创刊，现为完全开放获取期刊，研究癌症的分子基础及其对诊断和治疗的转化意义，2025 年期刊影响因子为 5.7。

Scope

• The journal examines all aspects of the molecular basis of cancer, with an explicit translational orientation towards diagnosis and therapy.期刊考察癌症分子基础的各个方面，并明确面向诊断与治疗的转化研究。
• Existing and emerging technologies, including genome sequencing, are covered where they clarify genomic and proteomic alterations within tumours.现有与新兴技术（包括基因组测序）只要有助于阐明肿瘤内的基因组与蛋白质组改变，均在收稿之列。
• Tumour pathogenesis, development and progression form a second core area.肿瘤发病机制、发生与发展构成第二个核心领域。
• Pharmacological work includes drug-drug interactions, mechanisms of action for novel agents and combination chemotherapy.药理学研究包括药物相互作用、新药作用机制与联合化疗。
• Pharmacogenomics, pharmacodynamics and pharmacokinetic properties of anticancer agents are treated as a distinct stream.抗癌药物的药物基因组学、药效学与药代动力学特征单列为一个方向。
• Anticancer chemotherapeutic agents, biological agents, immunomodulatory drugs, cell therapy and gene therapy all fall within the remit.抗癌化疗药物、生物制剂、免疫调节药物、细胞治疗与基因治疗均属收稿范围。
• The journal publishes original research, reviews, meeting reports, bedside-to-bench reports, letters to the editor and perspective articles.期刊发表原创研究、综述、会议报告、临床到实验台报告、致编辑的信与观点文章。

History

• The journal was founded in 2002 by Landes Bioscience in Austin, Texas, and volume 1 carried articles under the 10.4161 DOI prefix.本刊于 2002 年由（Landes Bioscience）在得克萨斯州奥斯汀创办，第 1 卷文章使用 10.4161 的 DOI 前缀。
• Taylor & Francis acquired Landes Bioscience in June 2014, and the title was absorbed into the Taylor & Francis journals programme.（Taylor & Francis）于 2014 年 6 月收购（Landes Bioscience），本刊随之并入其期刊出版体系。
• Print publication ended in 2022, when the print ISSN was retired and the journal converted to full open access from volume 23.2022 年纸本出版终止，印刷版 ISSN 同时停用，期刊自第 23 卷起转为完全开放获取。
• The 2025 Journal Impact Factor is 5.7, against 4.6 in 2024, 4.875 in 2022 and 4.742 in 2021, with a five-year impact factor of 4.5 and a CiteScore of 8.4.2025 年期刊影响因子为 5.7，2024 年为 4.6，2022 年为 4.875，2021 年为 4.742，五年影响因子为 4.5，CiteScore 为 8.4。
• It ranks 72nd of 333 titles in oncology in the 2025 Journal Citation Reports, placing it in the first quartile.在 2025 年期刊引证报告的肿瘤学 333 种期刊中，本刊列第 72 位，处于第一四分位。
• Publisher figures give an acceptance rate of 8 per cent, three days to a first decision, 52 days to a first post-review decision and ten days from acceptance to online publication.出版方数据显示，录用率为 8%，首次决定需三天，审后首次决定需 52 天，录用到在线发表需十天。

Editors

• Jonathan Brody of Oregon Health & Science University and Scott Waldman of Thomas Jefferson University are co-editors-in-chief.（Oregon Health & Science University）的（Jonathan Brody）与（Thomas Jefferson University）的（Scott Waldman）任共同主编。
• Dan Dixon of the University of Arkansas serves as deputy editor.（University of Arkansas）的（Dan Dixon）任副编辑。
• Twelve associate editors include Zoran Culig of the Medical University of Innsbruck, Randy Y.C. Poon of the Hong Kong University of Science and Technology and Bryan E. Strauss of the Sao Paulo Institute of Cancer.十二位副编辑包括（Medical University of Innsbruck）的（Zoran Culig）、（Hong Kong University of Science and Technology）的（Randy Y.C. Poon）与（Sao Paulo Institute of Cancer）的（Bryan E. Strauss）。
• The editorial board of about 34 members is weighted towards United States cancer centres such as MD Anderson, Johns Hopkins, Brown University, the University of Pennsylvania and the National Cancer Institute.约三十四人的编委会以美国癌症中心为主，如（MD Anderson）、（Johns Hopkins）、（Brown University）、（University of Pennsylvania）与（National Cancer Institute）。
• Review operates on a single-anonymized policy, and the journal reports 968,000 annual downloads and views.期刊采用单匿名评审政策，年下载与浏览量约 96.8 万次。
• Reviews are considered only when solicited by the editors, although pre-submission enquiries are accepted and answered before a review is invited.综述仅在编辑约稿时才受理，但作者可先作投稿前咨询，编辑会答复是否邀请投稿。